Market Overview

Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Share:

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that the Company will participate in the following conferences in March.

Portola Pharmaceuticals, Inc. Logo (PRNewsfoto/Portola Pharmaceuticals, Inc.®)

  • Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020, at 10:00 a.m. ET in Boston, MA.

     
  • Oppenheimer 30th Annual Healthcare Conference on Tuesday, March 17, 2020, at 2:45 p.m. ET in New York, NY.

Both presentations will be webcast live and available for replay in the Investor Relations section of the Portola website at http://investors.portola.com.

About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, a SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/portola-pharmaceuticals-to-participate-in-two-upcoming-investor-conferences-301008682.html

SOURCE Portola Pharmaceuticals, Inc.®

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com